List of Excipients in Branded Drug JENTADUETO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	JENTADUETO	linagliptin	54868-6461	ARGININE
Physicians Total Care Inc	JENTADUETO	linagliptin	54868-6461	COPOVIDONE
Physicians Total Care Inc	JENTADUETO	linagliptin	54868-6461	FERRIC OXIDE RED
Physicians Total Care Inc	JENTADUETO	linagliptin	54868-6461	HYPROMELLOSES

Jentadueto Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Jentadueto is a fixed-dose combination of linagliptin and metformin hydrochloride for type 2 diabetes. The immediate-release product creates opportunities in generic fixed-dose combinations, while Jentadueto XR offers greater formulation differentiation through modified-release technology. The strongest commercial opportunities are low-cost immediate-release tablets, once-daily extended-release tablets, and line extensions that improve gastrointestinal tolerability, swallowing, adherence, or supply resilience.

What is Jentadueto and which products are commercially relevant?

Jentadueto combines the DPP-4 inhibitor linagliptin with metformin hydrochloride. Boehringer Ingelheim markets linagliptin under the Tradjenta brand and the linagliptin/metformin combination under Jentadueto and Jentadueto XR.

Product	Active ingredients	Release profile	Typical dosing concept	Commercial significance
Jentadueto	Linagliptin plus metformin hydrochloride	Immediate release	Twice daily in many patients	Straightforward generic FDC opportunity
Jentadueto XR	Linagliptin plus metformin hydrochloride	Extended release	Once daily	Higher formulation and bioequivalence burden
Tradjenta	Linagliptin	Immediate release	Once daily	Competes with separate-component therapy
Generic metformin	Metformin hydrochloride	Immediate or extended release	Once or multiple times daily	Low-cost substitute and component product

FDA approved Jentadueto for adults with type 2 diabetes as an adjunct to diet and exercise. The product is not indicated for patients with type 1 diabetes or diabetic ketoacidosis. The labeling also includes renal-function restrictions associated with metformin use. [1]

Jentadueto XR uses the same pharmacologic combination but changes the delivery profile. That distinction matters because the commercial and regulatory barriers for an immediate-release fixed-dose combination are materially lower than for a once-daily extended-release product.

What excipients are used in Jentadueto?

The FDA labeling identifies common tablet and film-coating excipients for Jentadueto products, including arginine, corn starch, copovidone, magnesium stearate, hypromellose, talc, titanium dioxide, and colorants depending on strength and product presentation. Exact excipient composition can vary by strength and between immediate-release and extended-release products. [1, 2]

Functional role of the main excipients

Excipient	Likely function	Development relevance
Arginine	Processing and formulation aid; may support drug-substance handling	Can affect microenvironmental pH, blend properties, and tablet performance
Corn starch	Disintegrant and filler	Supports immediate-release breakup and drug dispersion
Copovidone	Binder and solubilization aid	Influences granulation, tablet strength, and dissolution
Magnesium stearate	Lubricant	Excess levels or over-lubrication can slow dissolution
Hypromellose	Film former or release-controlling polymer	Critical for coating integrity and, in XR products, release behavior
Talc	Anti-adherent and coating aid	Supports manufacturing and coating performance
Titanium dioxide	Opacifier and pigment	Affects appearance and coating opacity
Iron oxides or other colorants	Product identification	May be strength-specific

The excipient list does not establish that each ingredient is protected by a patent. Most commercial value lies in the formulation architecture, manufacturing process, particle engineering, coating system, or release-control mechanism rather than in the use of a standard excipient by itself.

What excipient strategy is appropriate for a Jentadueto generic?

The most practical strategy differs by dosage form.

Immediate-release Jentadueto

An immediate-release generic should prioritize:

1. Robust blend uniformity for low-dose linagliptin.
2. Rapid and reproducible metformin disintegration.
3. Low tablet weight relative to the high metformin load.
4. Acceptable hardness without delayed dissolution.
5. Low sensitivity to magnesium stearate concentration and lubrication time.
6. Coating stability under high-throughput production.
7. Compatibility with common direct-compression or wet-granulation equipment.

Linagliptin is present at a much lower dose than metformin. This creates a content-uniformity challenge. A formulation developer may use ordered mixing, geometric dilution, wet granulation, or a controlled premix to reduce segregation. The selected process must demonstrate uniformity at commercial scale, not only in laboratory batches.

Metformin hydrochloride has high dose loading and can produce large tablets. This creates pressure to increase compactability, reduce tablet volume, or use a bilayer architecture. A bilayer tablet can separate the two active ingredients physically, but it introduces additional process controls, compression complexity, and failure modes.

A conventional monolithic tablet is usually preferable when it can meet content-uniformity, dissolution, friability, and stability requirements. A bilayer design becomes more attractive when segregation, incompatibility, or dose-loading constraints cannot be controlled through a single-layer process.

Extended-release Jentadueto XR

Jentadueto XR requires a more differentiated excipient strategy. The primary technical objective is to control metformin release while maintaining rapid or appropriately timed linagliptin exposure.

Potential platforms include:

• Hydrophilic matrix tablets using hypromellose or related polymers.
• Hydrophilic-hydrophobic polymer blends.
• Coated matrix systems.
• Multilayer tablets.
• Multiparticulate systems compressed into tablets.
• Osmotic or membrane-controlled systems.

A hydrophilic matrix is generally the lowest-complexity platform. Polymer concentration, viscosity grade, particle size, compression force, and tablet geometry can materially affect release. A formulation that matches dissolution in one apparatus may diverge under another pH condition or agitation profile.

The key risks are dose dumping, excessive food effect, incomplete release, and inconsistent performance after scale-up. Metformin’s high dose and aqueous solubility make the release mechanism particularly sensitive to matrix erosion, gel formation, tablet dimensions, and gastrointestinal hydrodynamics.

What formulations are protected by Jentadueto-related intellectual property?

The commercial protection around Jentadueto can involve several layers:

IP layer	Typical protected subject matter	Relevance to a generic developer
Linagliptin compound patents	Chemical structure and pharmaceutical salts	May affect standalone linagliptin and combination products
Combination patents	Linagliptin plus metformin compositions or uses	Potential relevance to FDC development
Extended-release patents	Matrix, coating, release profile, or dosage regimen	More important for Jentadueto XR
Method-of-use patents	Treatment of type 2 diabetes or patient subgroups	May affect labeling strategy
Manufacturing patents	Granulation, blending, coating, or process controls	Can be avoided through an independent process
Patent-term extensions	Regulatory-delay adjustment for eligible patents	May extend enforceable patent life
Regulatory exclusivity	New-drug or formulation exclusivity	May restrict approval timing independently of patents

A formulation developer should not assume that copying the FDA-listed excipients creates infringement. Patent risk depends on the claims of each unexpired patent and on whether the proposed product practices those claims.

Jentadueto and Jentadueto XR have separate regulatory identities and may have different patent listings. The Orange Book should be reviewed by NDA, dosage form, strength, and product type. [3] Patent expiration should be determined from the live Orange Book listing and the underlying patent records, including any patent-term extension or pediatric adjustment.

When does Jentadueto lose exclusivity?

Jentadueto received FDA approval in the early 2010s, while Jentadueto XR was approved later as an extended-release formulation. The relevant loss-of-exclusivity date is not necessarily the same for:

• Linagliptin as a single agent.
• Immediate-release linagliptin/metformin tablets.
• Extended-release linagliptin/metformin tablets.
• Specific strengths.
• Listed method-of-use claims.
• Manufacturing or formulation patents.

A generic applicant should separate three dates:

1. Regulatory exclusivity expiry.
2. Patent expiry.
3. The earliest legally permissible ANDA launch date after any Paragraph IV litigation or settlement restrictions.

The absence of a listed patent does not guarantee immediate market entry. FDA approval, product-specific bioequivalence, manufacturing readiness, state substitution rules, and commercial launch decisions also affect entry timing.

What is the Orange Book status of Jentadueto?

Jentadueto products are prescription drugs approved under NDAs and may have Orange Book-listed patents associated with the relevant NDA. The Orange Book identifies patents that the NDA holder or applicant submits for approved drug substances, drug products, or methods of use. [3]

For diligence, the review should distinguish:

Review item	Question
NDA 201281	Which patents are listed for immediate-release Jentadueto?
Jentadueto XR NDA	Which patents are listed for the extended-release product?
Strength	Are all strengths covered by the same listed patents?
Use code	Does a method-of-use patent cover the proposed label?
Expiry	Is the expiration date adjusted for patent-term extension or pediatric exclusivity?
Litigation	Has a Paragraph IV notice triggered a Hatch-Waxman action?
Settlement	Does an agreement permit an authorized or licensed generic before patent expiry?

Patent listings can change. A transaction or launch analysis should use an Orange Book snapshot dated close to the decision date rather than relying on an old patent summary.

Which companies are challenging Jentadueto?

Generic competition can come from manufacturers developing:

• Immediate-release linagliptin/metformin tablets.
• Extended-release linagliptin/metformin tablets.
• Separate linagliptin and metformin products.
• Other DPP-4/metformin combinations.
• SGLT2/metformin or GLP-1-based alternatives.

Publicly identifying every active challenger requires current FDA ANDA data, Paragraph IV notices, court dockets, and commercial launch records. An ANDA applicant may remain commercially invisible until FDA approval, litigation disclosure, or product launch.

The principal competitive threat is not limited to a direct Jentadueto substitute. Metformin plus a separate DPP-4 inhibitor can reproduce the clinical regimen, while newer diabetes therapies compete for the same prescribing decision with different efficacy, weight, cardiovascular, or renal profiles.

What Paragraph IV risks affect a Jentadueto generic?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. For Jentadueto, risk can arise from claims directed to:

• The linagliptin active ingredient.
• The combination of linagliptin and metformin.
• Extended-release tablet architecture.
• Specific release profiles.
• Methods of treating diabetes.
• Formulation or manufacturing processes.

A first-filer position may create 180-day generic exclusivity if the statutory conditions are satisfied. That opportunity can be commercially valuable, but it also carries litigation cost and launch-delay risk.

Immediate-release products usually offer a simpler design-around path than XR products. An applicant can select different binders, disintegrants, coating materials, or processing conditions if the resulting product meets FDA requirements and avoids the relevant patent claims. Extended-release products may require more substantial engineering because the delivery mechanism itself can be central to the patent estate.

What regulatory requirements apply to a Jentadueto generic?

A conventional ANDA must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. FDA product-specific guidance, where available, should control study design. [4]

Immediate-release requirements

The development package normally focuses on:

• Same active ingredients, strengths, dosage form, and route.
• Content uniformity.
• Comparative dissolution across relevant media.
• Fasting and fed bioequivalence where required.
• Stability under ICH conditions.
• Impurity and degradation control.
• Inactive-ingredient safety.
• Manufacturing-process validation.

FDA generally permits an ANDA formulation to use different inactive ingredients from the reference product. The proposed excipients must be suitable for the dosage form, route, strength, and patient population. Changes that affect absorption, tolerability, or product performance can create regulatory risk.

Extended-release requirements

XR development adds:

• Comparative release profiles.
• Food-effect assessment.
• Alcohol-induced dose-dumping evaluation where applicable.
• Multiple-strength proportionality or bridging.
• Robustness to manufacturing variation.
• In vitro-in vivo correlation considerations.
• Demonstration that the entire metformin dose is delivered as intended.

The challenge is not simply matching an average dissolution curve. The product must maintain performance across manufacturing lots and clinically relevant conditions.

How strong is the Jentadueto patent estate?

The patent estate is likely stronger for an XR product than for a conventional immediate-release tablet because modified-release delivery creates more claimable technical features. The strength of any individual patent depends on claim scope, prior art, prosecution history, validity, and whether the proposed generic practices the asserted claims.

Dimension	Immediate-release Jentadueto	Jentadueto XR
Excipient design-around potential	High	Moderate
Process design-around potential	High	Moderate
Dissolution complexity	Moderate	High
Bioequivalence burden	Moderate	High
Risk from release-profile claims	Low to moderate	High
Manufacturing scale-up risk	Moderate	High
Commercial launch complexity	Moderate	High

Standard excipients such as starch, copovidone, hypromellose, talc, and magnesium stearate are widely used and generally provide substantial design flexibility. Risk increases when patent claims define a specific polymer system, ratio, release profile, tablet structure, or manufacturing sequence.

What commercial opportunities exist for Jentadueto excipients?

Low-cost immediate-release generic

This is the clearest opportunity. A manufacturer can use a conventional excipient system, optimize high-dose metformin compression, and compete through:

• Low manufacturing cost.
• Reliable supply of metformin and linagliptin.
• Fewer tablet defects.
• Smaller tablet size.
• Contract manufacturing for regional distributors.
• Private-label or authorized-generic arrangements.

Once-daily extended-release product

Jentadueto XR offers higher technical barriers and potentially better differentiation. Commercial value depends on whether the developer can achieve:

• Once-daily dosing.
• Stable release across strengths.
• Limited food effect.
• Competitive tablet size.
• Low variability after scale-up.
• A noninfringing release-control system.

Excipient suppliers

Excipient companies can pursue opportunities in:

• Direct-compression grades that improve high-dose metformin compactability.
• Copovidone grades that improve binder efficiency.
• Low-viscosity or controlled-viscosity hypromellose for XR matrices.
• Co-processed excipients that reduce segregation.
• Lubricant systems that preserve dissolution.
• Film-coating systems with lower weight gain.
• Excipients supporting smaller tablets or bilayer compression.

The strongest supplier proposition is a validated formulation package rather than an isolated raw material. A co-processed or platform excipient can command greater value if it reduces development time, improves scale-up, and supports multiple strengths.

Regional and emerging-market FDCs

Fixed-dose combinations remain commercially relevant where pill burden, adherence, and pharmacy substitution influence prescribing. Opportunities are strongest in markets with:

• High metformin use.
• Limited access to newer diabetes therapies.
• Established generic substitution.
• Demand for once-daily regimens.
• Local manufacturing incentives.

Geographic freedom-to-operate must be assessed separately. U.S. patent status does not establish freedom to commercialize in Europe, China, India, Brazil, or other jurisdictions.

What manufacturing and IP barriers affect Jentadueto development?

The principal manufacturing barriers are blend segregation, high metformin loading, tablet-size control, coating defects, and XR dissolution variability. The principal IP barriers are linagliptin composition claims, combination claims, modified-release claims, method-of-use claims, and process patents.

A design-around program should assess:

1. Alternative granulation and blending routes.
2. Different binder and disintegrant systems.
3. Separate granulation of linagliptin and metformin.
4. Bilayer versus monolithic compression.
5. Alternative XR polymers and coating systems.
6. Distinct tablet geometry.
7. Independent manufacturing parameters.
8. Noninfringing release specifications.

The development record should document why the formulation was selected and how it differs from patent claim elements. That record supports both regulatory filing and litigation defense.

How does Jentadueto compare with competing diabetes combinations?

Product category	Main advantage	Excipient opportunity	Competitive pressure
Jentadueto IR generic	Low development complexity	Conventional tablet optimization	High from low-cost alternatives
Jentadueto XR generic	Once-daily dosing	Matrix and coating innovation	Moderate to high
Linagliptin plus separate metformin	Flexible dosing	Standard separate products	Strong substitution threat
Sitagliptin/metformin	Established FDC category	Similar high-dose metformin issues	Direct DPP-4 competition
SGLT2/metformin combinations	Weight, cardiovascular, or renal positioning	Modified release and dual-layer designs	Stronger clinical differentiation
GLP-1 products	Greater efficacy and weight-loss positioning	Injectable or oral delivery systems	High commercial substitution risk

Jentadueto is most exposed to low-cost DPP-4 alternatives and separate-component prescribing. Its commercial position is less protected by excipient differentiation than by convenience, formulary placement, price, and supply reliability.

What revenue exposure does Jentadueto create?

Revenue exposure should be measured at the franchise level rather than by Jentadueto alone. Generic entry can affect:

• Jentadueto prescription volume.
• Tradjenta prescribing.
• Net price and rebate levels.
• Hospital and payer formulary position.
• Inventory write-down risk.
• Authorized-generic strategy.
• Contract manufacturing demand.

Immediate-release generic entry generally creates the earliest price pressure. XR products may retain higher gross margins if they face more difficult bioequivalence and formulation barriers. The size of the opportunity depends on market share, current net sales, payer substitution, and the number of approved competitors.

Key Takeaways

• Jentadueto combines linagliptin and metformin hydrochloride; Jentadueto XR adds a modified-release formulation challenge.
• Immediate-release development is primarily a content-uniformity, tablet-size, dissolution, and cost-control exercise.
• XR development requires control of polymer hydration, erosion, food effect, and dose-dumping risk.
• Standard excipients are generally design-around tools rather than the core source of patent protection.
• The strongest excipient opportunities are high-dose metformin compression systems, segregation-control platforms, and XR matrix technologies.
• Orange Book listings, patent expiry, Paragraph IV activity, and settlement terms must be assessed separately for immediate-release and XR products.
• Generic competition includes direct FDCs, separate linagliptin and metformin therapy, and newer diabetes combinations.
• The commercial case is strongest for a low-cost IR generic or a technically differentiated once-daily XR product with reliable supply.

FAQs

Is Jentadueto an immediate-release or extended-release product?

Jentadueto is the immediate-release product. Jentadueto XR is the extended-release version intended for once-daily administration.

Can a generic Jentadueto use different excipients?

Yes. An ANDA may use different inactive ingredients if the formulation satisfies FDA safety, quality, pharmaceutical-equivalence, and bioequivalence requirements.

Which excipient is most important in Jentadueto XR?

The release-controlling polymer system is usually the most important formulation variable. Hypromellose type, viscosity, concentration, particle size, and compression conditions can materially affect metformin release.

Is an authorized generic the same as a licensed generic?

An authorized generic is generally marketed by or with permission from the brand sponsor under the approved NDA, while an ANDA generic is approved through the abbreviated pathway and may challenge listed patents.

Are biosimilar rules relevant to Jentadueto?

No. Jentadueto is a small-molecule drug product, so generic-drug rules under the ANDA pathway apply. Biosimilar rules apply to biological products, not linagliptin/metformin tablets.

References

1. U.S. Food and Drug Administration. (2024). Jentadueto (linagliptin and metformin hydrochloride) tablets: Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets: Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development